Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free VLG Stock Alerts

Venture Life Group (VLG) Competitors

Venture Life Group logo
GBX 70 0.00 (0.00%)
As of 12:27 PM Eastern
Compare

VLG vs. AGY, BXP, ANCR, BVXP, and ORPH

Should you buy Venture Life Group stock or one of its competitors? Venture Life Group's main competitors and comparable companies include Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Bioventix (BVXP), and Open Orphan (ORPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Venture Life Group compare to Allergy Therapeutics?

Venture Life Group (LON:VLG) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Venture Life Group had 8 more articles in the media than Allergy Therapeutics. MarketBeat recorded 8 mentions for Venture Life Group and 0 mentions for Allergy Therapeutics. Venture Life Group's average media sentiment score of 1.22 beat Allergy Therapeutics' score of 0.00 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Positive
Allergy Therapeutics Neutral

Venture Life Group has a beta of 0.234, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, indicating that its stock price is 17% less volatile than the broader market.

Venture Life Group has higher earnings, but lower revenue than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3716.02
Allergy Therapeutics£57.29M5.33-£52.59M-£0.97N/A

Venture Life Group has a net margin of 17.42% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Allergy Therapeutics -85.46%409.00%-34.76%

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by company insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Venture Life Group beats Allergy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Beximco Pharmaceuticals?

Venture Life Group (LON:VLG) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Venture Life Group had 8 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 8 mentions for Venture Life Group and 0 mentions for Beximco Pharmaceuticals. Venture Life Group's average media sentiment score of 1.22 beat Beximco Pharmaceuticals' score of 0.08 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Positive
Beximco Pharmaceuticals Neutral

Venture Life Group has a beta of 0.234, indicating that its share price is 77% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, indicating that its share price is 75% less volatile than the broader market.

21.9% of Venture Life Group shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 7.5% of Venture Life Group shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Venture Life Group has a net margin of 17.42% compared to Beximco Pharmaceuticals' net margin of 16.04%. Beximco Pharmaceuticals' return on equity of 15.25% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Beximco Pharmaceuticals 16.04%15.25%6.97%

Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3716.02
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03

Summary

Venture Life Group beats Beximco Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Venture Life Group has a net margin of 17.42% compared to Animalcare Group's net margin of 5.70%. Venture Life Group's return on equity of 7.82% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Venture Life Group 17.42%7.82%1.56%

14.3% of Animalcare Group shares are held by institutional investors. Comparatively, 21.9% of Venture Life Group shares are held by institutional investors. 30.1% of Animalcare Group shares are held by company insiders. Comparatively, 7.5% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Venture Life Group had 8 more articles in the media than Animalcare Group. MarketBeat recorded 8 mentions for Venture Life Group and 0 mentions for Animalcare Group. Venture Life Group's average media sentiment score of 1.22 beat Animalcare Group's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Animalcare Group Neutral
Venture Life Group Positive

Animalcare Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£89.11M2.60£36.55M£7.3045.89
Venture Life Group£35.17M2.39£747.21K£4.3716.02

Animalcare Group has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, meaning that its share price is 77% less volatile than the broader market.

Summary

Animalcare Group beats Venture Life Group on 8 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Bioventix?

Venture Life Group (LON:VLG) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by company insiders. Comparatively, 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Venture Life Group had 8 more articles in the media than Bioventix. MarketBeat recorded 8 mentions for Venture Life Group and 0 mentions for Bioventix. Venture Life Group's average media sentiment score of 1.22 beat Bioventix's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Positive
Bioventix Neutral

Venture Life Group has a beta of 0.234, meaning that its share price is 77% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.555, meaning that its share price is 45% less volatile than the broader market.

Bioventix has lower revenue, but higher earnings than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3716.02
Bioventix£12.54M7.02£8.12M£140.5211.99

Bioventix has a net margin of 59.30% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 65.83% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Bioventix 59.30%65.83%54.07%

Summary

Bioventix beats Venture Life Group on 7 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Open Orphan?

Venture Life Group (LON:VLG) and Open Orphan (LON:ORPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Venture Life Group has higher revenue and earnings than Open Orphan.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3716.02
Open Orphan£34.71M0.00N/AN/AN/A

21.9% of Venture Life Group shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Open Orphan's net margin of 0.00%. Venture Life Group's return on equity of 7.82% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Open Orphan N/A N/A N/A

In the previous week, Venture Life Group had 8 more articles in the media than Open Orphan. MarketBeat recorded 8 mentions for Venture Life Group and 0 mentions for Open Orphan. Venture Life Group's average media sentiment score of 1.22 beat Open Orphan's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Positive
Open Orphan Neutral

Summary

Venture Life Group beats Open Orphan on 9 of the 9 factors compared between the two stocks.

Get Venture Life Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VLG vs. The Competition

Export
MetricVenture Life GroupPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£84.03M£12.20B£7.10B£2.83B
Dividend Yield0.09%2.65%2.54%6.26%
P/E Ratio16.02799.74273.67366.32
Price / Sales2.39845.62595.4789,071.63
Price / Cash6.4015.0827.2227.89
Price / Book1.1910.6611.096.96
Net Income£747.21K£2.84B£3.49B£5.89B
7 Day Performance7.69%-2.20%-2.28%-0.62%
1 Month Performance7.03%-6.95%-7.03%-1.07%
1 Year Performance30.38%-4.97%5.66%22.84%

Venture Life Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VLG
Venture Life Group
N/AGBX 70
flat		N/A+27.3%£84.03M£35.17M16.02165
AGY
Allergy Therapeutics
N/AGBX 5
flat		N/A-43.2%£316.63M£57.29MN/A612
BXP
Beximco Pharmaceuticals
N/AGBX 55.66
-4.4%		N/A+28.2%£248.31M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat		N/AN/A£231.30M£89.11M45.89220
BVXP
Bioventix
N/AGBX 1,650
+3.1%		N/A-30.9%£86.21M£12.54M11.7412

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:VLG) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...
Brownstone Research | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...
Stansberry Research | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel